← Back to patent-cliff list
CAS 1432922-28-5
13-amino-2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecine-12-carbonitrile
Codes：ICOT-021
Application context (from source-drug indications)
非小细胞肺癌盐酸埃克替尼肺腺癌盐酸埃克替尼支气管肿瘤盐酸埃克替尼肺癌盐酸埃克替尼转移性乳腺癌盐酸埃克替尼银屑病盐酸埃克替尼
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 盐酸埃克替尼Icotinib Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate)→3-ethynylaniline→3,4-dihydroxybenzonitrile→2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecine-12-carbonitrile→13-nitro-2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecine-12-carbonitrile→13-amino-2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecine-12-carbonitrile→(E)-N'-(13-cyano-2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecin-12-yl)-N,N-dimethylformimidamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.